PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease

Blog
Video

The deputy director, Division of Rare Diseases Research Innovation, NCATS, NIH, discussed areas that the agency is targeting.

“I think there's a real opportunity for some major change that could really benefit the whole field, realizing that it's not a trivial thing to do - to change the newborn screening system in the United States that's been around for a long time. But I think it's important to have those discussions because the current newborn screening doesn't fit the therapeutic strategies we have.”

Many challenges face the development of novel therapies for underserved populations with rare diseases, including rarity, biotech support, clinical trial recruitment, and heterogeneity. The National Institutes of Health (NIH) aims to help facilitate rare disease drug development and has several initiatives it is pursuing to this end.

CGTLive® spoke with PJ Brooks, PhD, deputy director, Division of Rare Diseases Research Innovation, National Center for Advancing Translational Science (NCATS), NIH, to learn more about the topics that the NIH and NCATS are focusing that they believe are important to improve accessibility of gene therapies. Brooks emphasized that although much progress has been made in the field of neuromuscular disease with new, novel therapies, there are still many challenges facing novel therapy accessibility in the field and for other rare diseases in which gene therapy development is ongoing.

Important areas of focus that NCATS and NIH ishoning in on include newborn screening and developing more non-viral gene editing strategies.Brooks stressed that current newborn screening strategies do not align with the evolving therapeutics landscape. Some other programs the NIH is working on include the platform vector gene therapies project and the Bespoke Gene Therapy Consortium (BGTC) that aims to develop a platform that can produce bespoke gene therapies for rare diseases.

Recent Videos
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Related Content
© 2025 MJH Life Sciences

All rights reserved.